Single Source: NINDS Exploratory Clinical Trials (U01 Clinical Trial Required)
ID: 354402Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Award Range

$0 - $2M

Eligible Applicants

Small Businesses

Funding Category

Health

Funding Instrument

Cooperative Agreement

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/354402

Additional Information

http://grants.nih.gov/grants/guide/pa-files/PAR-24-215.html
Timeline
    Description

    The National Institutes of Health (NIH) is offering a non-competitive funding opportunity through a cooperative agreement to support the Hennepin Healthcare Research Institute in renewing the Phase II Hyperbaric Oxygen Brain Injury Treatment (HOBIT) clinical trial. This initiative aims to investigate the effectiveness and safety of hyperbaric oxygen therapy for individuals with severe traumatic brain injury, continuing participant randomization, follow-up, trial closure activities, and dissemination of results. The funding opportunity reflects NIH's commitment to advancing research in neurological disorders and trauma, with a maximum award amount of $2 million per year for a project duration of up to five years. Interested applicants must adhere to the application guidelines outlined in the NIH application guide and submit their proposals by July 24, 2024, at 5:00 PM local time. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov.

    Point(s) of Contact
    grantsinfo@nih.gov
    Files
    Title
    Posted
    PAR-24-215-Full-Announcement.html
    PAR-24-215.html
    The National Institute of Neurological Disorders and Stroke (NINDS) is issuing a non-competitive funding opportunity to support a single-source cooperative agreement for the Hennepin Healthcare Research Institute. The funding aims to renew support for the Phase II Hyperbaric Oxygen Brain Injury Treatment (HOBIT) clinical trial, designed to explore the effectiveness and safety of hyperbaric oxygen therapy for severe traumatic brain injury. The project will continue randomization and follow-up of participants, along with trial closure activities and dissemination of results. A maximum of $2 million in total costs per year is anticipated, with a project duration of up to five years. The application process requires adherence to strict guidelines, addressing all instructions outlined in the NIH application guide. Eligible applicants are limited to Hennepin Healthcare Research Institute, and submissions may be made via NIH ASSIST, Grants.gov Workspace, or a system-to-system solution. Applications must be submitted by 5:00 PM local time on the due date, with a review cycle set to take place subsequently. This funding opportunity reflects NINDS's commitment to advancing research in neurological disorders and trauma while fostering collaboration among academic institutions.
    Similar Opportunities
    BRAIN Initiative: Clinical Studies to Advance Next-Generation Devices for Recording and Modulation in the Human Central Nervous System (UH3 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity under the BRAIN Initiative to support clinical studies aimed at advancing next-generation devices for recording and modulation within the human central nervous system (CNS). This initiative encourages proposals for early-stage clinical investigations, including first-in-human studies, that focus on treating CNS disorders and enhancing understanding of brain functions, particularly through Significant Risk studies requiring FDA Investigational Device Exemptions (IDEs) for chronic implants. The NIH plans to allocate approximately $10 million annually to fund 5 to 7 projects, emphasizing the importance of collaborations with device manufacturers through a public-private partnership program, and requires a Plan for Enhancing Diverse Perspectives as part of the application. Interested applicants can find more information and submit inquiries via grantsinfo@nih.gov, with the application deadline set for January 28, 2027.
    NIH StrokeNet Clinical Trials and Biomarker Studies for Stroke Treatment, Recovery, and Prevention (UG3/UH3 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "NIH StrokeNet Clinical Trials and Biomarker Studies for Stroke Treatment, Recovery, and Prevention (UG3/UH3 Clinical Trial Optional)." This initiative aims to support multi-site exploratory and confirmatory clinical trials that focus on innovative interventions, biomarker validation, and ancillary studies related to stroke prevention, treatment, and recovery. The program emphasizes collaboration within the NIH StrokeNet infrastructure to enhance patient recruitment and trial execution, addressing critical public health issues associated with stroke. Interested applicants must submit their proposals by November 19, 2026, and can find additional information and application details at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov.
    Clinical Validation of a Candidate Biomarker for Neurological or Neuromuscular Disorders (U44 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity for the clinical validation of candidate biomarkers for neurological and neuromuscular disorders through the U44 Cooperative Agreement mechanism. This initiative aims to rigorously validate biomarkers that have already been identified and for which detection methods have been developed, ensuring compliance with FDA guidelines to establish their clinical sensitivity and specificity. This program is crucial for advancing therapeutic development in the field of brain health, with funding potentially reaching $700,000 for Phase I and $1.5 million for Phase II projects. Interested applicants must adhere to specific submission guidelines and deadlines, with the application closing on June 22, 2026. For further information, applicants can contact NIH Grants Information at grantsinfo@nih.gov or visit the opportunity's webpage at https://grants.nih.gov/grants/guide/pa-files/PAR-24-096.html.
    Solutions to enable diagnosis and treatment of adverse health consequences of non-disordered drug use (R43/R44 - Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Solutions to enable diagnosis and treatment of adverse health consequences of non-disordered drug use (R43/R44 - Clinical Trial Optional)" aimed at supporting Small Business Innovation Research (SBIR) proposals. This initiative seeks innovative, accessible, and affordable solutions to address health complications arising from non-disordered drug use, including issues such as hypoxia-related brain injuries from opioid overdoses and cardiovascular problems from stimulant use. The program anticipates a total budget of $2 million for approximately 2-5 awards in Fiscal Year 2025, with applications due by December 2, 2024. Interested applicants can find more information and guidelines at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    NINDS Efficacy Clinical Trials (UG3/UH3 Clinical Trial Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity for investigator-initiated efficacy clinical trials through the NINDS Efficacy Clinical Trials (UG3/UH3 Clinical Trial Required) program. This initiative aims to support clinical studies that evaluate drugs, biologics, devices, and various interventions targeting neurological disorders, requiring a phased approach where UG3 planning must precede UH3 execution. The trials must be well-designed with robust scientific rationale and diverse participant inclusion, emphasizing collaboration with patient advocacy groups and national networks. Interested applicants can find more information and application guidelines at the provided NIH link, with a submission deadline of January 9, 2025, and no cost-sharing or matching requirements. For inquiries, contact the NIH OER Webmaster at grantsinfo@nih.gov.
    BRAIN Initiative: Research on the Ethical Implications of Advancements in Neurotechnology and Brain Science (R21 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity under the BRAIN Initiative for research on the ethical implications of advancements in neurotechnology and brain science, designated as R21 Clinical Trial Optional grants. This initiative invites multi-disciplinary teams to explore critical ethical issues related to brain research, including topics such as brain imaging, data privacy, and informed consent, with the aim of fostering diverse collaborations and addressing significant ethical challenges in the field. The total funding available is $2 million annually over three years, supporting up to eight new awards, with individual project budgets capped at $275,000 for a two-year period. Interested applicants should note that the application period opens on September 11, 2024, and closes on October 9, 2026; for further inquiries, they can contact NIH Grants Information at grantsinfo@nih.gov.
    Prospective Observational Comparative Effectiveness Research in Clinical Neurosciences (UG3/UH3 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity for prospective observational comparative effectiveness research (CER) in clinical neurosciences, specifically through the National Institute of Neurological Disorders and Stroke (NINDS). This initiative aims to encourage grant applications that investigate preventive strategies, diagnostic approaches, and various interventions, including drugs, devices, and therapies, that align with NINDS's mission. The funding mechanism follows a UG3/UH3 cooperative agreement structure, starting with a 2-year planning phase (UG3) that may transition into a 5-year observational study phase (UH3) upon meeting specific milestones. Interested applicants, including a diverse range of organizations, must submit their applications by May 7, 2025, and can find more information at the provided NIH link or contact the NIH OER Webmaster at OERWebmaster03@od.nih.gov for inquiries.
    NHLBI Early Phase Clinical Trials for Therapeutics and/or Diagnostics for HLBS Disorders (R33 CT Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity for the NHLBI Early Phase Clinical Trials (R33), aimed at supporting investigator-initiated Phase I clinical trials for therapeutic and diagnostic interventions targeting heart, lung, blood, and sleep (HLBS) disorders. Applicants are required to be prepared to initiate their clinical trials within the first quarter of the project period and must demonstrate readiness in obtaining necessary regulatory approvals, including FDA and IRB, prior to the award. This funding is crucial for addressing unmet medical needs through innovative research, with a maximum budget of $1.515 million per year and a project duration of up to three years, contingent upon achieving specific milestones. Interested applicants should note the application deadline of June 4, 2024, and can direct inquiries to NIH Grants Information at grantsinfo@nih.gov for further details.
    Clinical Trial Readiness for Functional Neurological Disorders (U01 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting applications for a funding opportunity titled "Clinical Trial Readiness for Functional Neurological Disorders (U01 Clinical Trial Optional)," aimed at enhancing clinical trial methodologies for Functional Neurological Disorders (FNDs). This initiative seeks to address critical challenges in the diagnosis and management of FNDs by encouraging the validation of biomarkers and clinical outcome assessments (COAs) that are specifically tailored for clinical trials. Given the significant healthcare burden posed by FNDs, which often require interdisciplinary approaches for effective management, this funding opportunity emphasizes the need for robust clinical evidence to improve treatment strategies and patient outcomes. Interested applicants, including a diverse range of organizations such as higher education institutions and community-based organizations, must submit their proposals by November 5, 2024, with funding contingent on NIH appropriations. For further inquiries, applicants can contact the NIH OER Webmaster at OERWebmaster03@od.nih.gov.
    NINDS Exploratory Clinical Trials for Small Business (R43/R44 Clinical Trial Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity for small business concerns (SBCs) through the NINDS Exploratory Clinical Trials program (R43/R44), aimed at supporting investigator-initiated exploratory clinical trials related to neurological disorders. This program invites applications for studies that evaluate drugs, biologics, devices, or therapies, generating preliminary data to inform future clinical development, with a focus on enhancing diverse perspectives within research teams. Eligible U.S.-based SBCs can apply for funding caps of up to $295,924 for Phase I and $1,972,828 for Phase II, with applications due by September 5, 2026. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov or visit the additional information link at https://grants.nih.gov/grants/guide/pa-files/PAR-23-311.html.